Video Gallery
Mark Emalfarb, CEO (Nasdaq:DYAI) on YAHOO Finance On The Move to discuss the spread of Coronavirus
Mark Emalfarb / TD Ameritrade Interview “The Watch List”
#TradeTalks: Getting Ahead of the Curve on Pandemic & Biological Threats with Synthetic Biology
Dyadic Getting Ahead of the Curve on Coronavirus Cure, CEO Says
Dyadic CEO Mark Emalfarb interviewed by Liz Claman “The Claman Countdown” from FOX Business Network - Monday, January 27, 2020
Dyadic CEO remarks on steps the federal gov't can take to speed along drug manufacturing
Dyadic International reveals recent 4Q highlights and upcoming milestones
Dyadic International announces collaboration with leading animal health company
Mark Emalfarb on Improving Access and Cost to the Global Healthcare Sector
Update with Dyadic International, Inc. (NASDAQ: DYAI) -SNN Network at RHK Capital’s September 2019 Conference
Dyadic International reveals newest research collaboration, Proactive Investors - August 14, 2019
Zacks analyst John Vandermosten bullish on Dyadic International's C1 gene expression platform - July 16, 2019
Dyadic International Board Member Highlights Upcoming Milestones - July 2, 2019
Nasdaq #BehindtheBell Dyadic International DYAI - June 17, 2019
Dyadic – The Watch List TD Ameritrade - June 17, 2019
Dyadic International to ring Nasdaq closing bell (Part 2 of 2) - June 17, 2019
Dyadic International to ring Nasdaq closing bell (Part 1 of 2) - June 17, 2019
Dyadic – Nasdaq June 17, 2019 Bell Ringing
Dyadic International Chairman highlights recent Serum Institute of India collaboration - May 30, 2019
Dyadic International posts higher revenue from R&D, new sublicensing collaborations - May 10, 2019
Dyadic International forms agreement with contract manufacturing organization Luina Bio - May 2, 2019
Dyadic International CEO reflects on 2018 accomplishments and reveals year-end earnings - March 28, 2019
Dyadic International says up-listing to the NASDAQ is 'part of the plan', February 13, 2018
Mark Emalfarb interviewed: IPO podcast series from Channelchek January 28, 2019
Mark Emalfarb Interviewed at Biotech Showcase January 2019
Matthew S. Jones, Managing Director, Business Development & Licensing, sat down with Christine Corrado from Proactive Investors at the 11th Annual Biotech Showcase in San Francisco January 2019
Biotech and Money, Investival Showcase Jefferies November 13, 2018
Dyadic International Inc stock ticks up on partnership announcement
Dyadic International Teaming Up Top Tier Biopharmaceutical Company
14th Annual PEGS Boston Conference – The Essential Protein Engineering Summit May 3, 2018
Dyadic CEO & CCO Interviewed by OTC Markets Group, February 2018
Dyadic International, Inc. (OTCQX: DYAI) Inv€$table Showcase Biotech and Money November 2017
Dyadic International, Inc. (OTCQX: DYAI) Virtual Investor Conference October 2017
Dyadic International, Inc. (OTCQX: DYAI) The Innovation Show – August 2017 | From Stonewashed Jeans to Lifesaving Genes
Dyadic Seeks to Bring Disruptive Technology to Biomanufacturing, The Bio Report, June 2017
Update with Dyadic International, Inc. (OTCQX: DYAI) - October 2016 | Stock News Now
Dyadic International, Inc. (OTCQX: DYAI): Managing Director, Biz Dev/Licensing | Stock News Now
Dyadic International, Inc. (OTCQX: DYAI) with CSO - October 2016 | Stock News Now
SCN’s Wendy Gillette Interview of Dyadic Intl (DYAI) CEO Mark Emalfarb Conducted at the NASDAQ MarketSite Informative on
July 26, 2016
Dyadic’s CEO Mark Emalfarb Interview with Stock News Now,
June 2016
Dyadic’s CEO Mark Emalfarb, Details Company’s Inflection Point May 6, 2016 – NYC, PIONEERS 2016, Joseph Gunnar & Co.